Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx ...

The Federal Trade Commission sued the three dominant pharmacy-benefit managers ... According to the FTC, the three largest PBMs — CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth’s ...

Express Scripts by Evernorth, a subsidiary of The Cigna Group (NYSE: CI), today issued the following statement in response to the Federal Trade Commission's reckless insulin action: ...

The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes ...

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, ...

The suit accuses the "Big Three" of steering diabetes patients toward high-priced insulin to benefit their bottom lines ...

The US Federal Trade Commission is accusing units of CVS, Cigna, and UnitedHealth of engaging in illegal rebate programs that drove up the price of insulin. Federal Trade Commission Office of Public ...

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.